Immunocore Holdings plc
IMCR Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$30.98
KIRA · Stoqly’s AI analyst, in plain words
- Immunocore Holdings plc had $400M of revenue in fiscal 2025, up 29.0% on the year before.
- Its operating margin was −11.3%, up 11.4 pts: of every 100 in sales, about −11 is left after running the business.
- Immunocore Holdings plc lost $35.5M in fiscal 2025.
- Free cash flow was −$15.1M in fiscal 2025, −3.8% of revenue.
Market cap
$1.6B
P/E
—
Revenue
$400M
Net income
−$35.5M
Free cash flow
−$15.1M
Operating margin
−11.3%
Immunocore Holdings plc in 30 seconds · fiscal 2025
Are sales growing?
+29.0%
Yes. Sales grew 29.0% last year.
Does it make a profit?
−8.9%
No. It lost money last year.
Does profit turn into cash?
−3.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Immunocore Holdings plc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- Immunocore Holdings plc
- CIK
- 0001671927
Immunocore Holdings plc · IMCR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $36.5M | $174M | $249M | $310M | $400M |
| Revenue growth | — | 377.9% | 43.1% | 24.4% | 29.0% |
| Gross margin | 100.0% | 99.4% | 99.6% | 99.1% | 98.7% |
| Operating margin | −478.5% | −29.7% | −23.9% | −22.7% | −11.3% |
| Net income | −$180M | −$52.5M | −$55.3M | −$51.1M | −$35.5M |
| Net margin | −493.4% | −30.1% | −22.2% | −16.5% | −8.9% |
| Diluted EPS | −$4.24 | −$1.15 | −$1.13 | −$1.02 | −$0.71 |
| Cash | |||||
| Cash from operations | −$143M | −$49.2M | $2.9M | $26.1M | −$10.7M |
| Capital expenditure | $1.4M | $2.2M | $5.4M | $5.2M | $4.3M |
| Free cash flow | −$144M | −$51.4M | −$2.5M | $20.9M | −$15.1M |
| FCF margin | −396.0% | −29.5% | −1.0% | 6.7% | −3.8% |
| Share count change | — | 7.6% | 6.9% | 2.3% | 0.7% |
| Debt and strength | |||||
| Cash and short-term investments | $321M | $402M | $443M | $820M | $864M |
| Shareholders' equity | $234M | $339M | $369M | $361M | $381M |
| Current ratio | — | 4.7x | 3.8x | 4.4x | 4.0x |
| Interest coverage | −31.3x | −9.6x | −11.6x | −3.7x | −3.7x |
| Returns and quality | |||||
| Return on equity | −77.0% | −18.4% | −15.6% | −14.0% | −9.6% |
| Return on tangible equity | −77.0% | −15.5% | −15.0% | −14.2% | −9.3% |
| Piotroski F-score | — | — | 5 | 4 | 3 |
| Altman Z'' | — | 1.6 | 1.2 | 2.2 | 2.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$5.6M
4 insiders
Of sales under plans
89%
$5.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Immunocore Holdings plc · IMCR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $30.98 a share, the company is worth $1.6B.
Source: SEC EDGAR XBRL filings (CIK 0001671927). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.